Hosted on MSN1d
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
FiercePharma1d
Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...
ENDPOINTS NEWS20h
Cat­a­lyst staves off Fir­dapse com­pe­ti­tion from Te­va for a decade
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
Zacks.com on MSN1d
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Catalyst Pharmaceuticals in Settlement With Teva of Firdapse Patent Litigation
Catalyst Pharmaceuticals and its licensor SERB entered into a settlement agreement with Teva Pharmaceuticals resolving patent litigation brought by Catalyst and SERB in response to Teva's plans for a ...